Journal
HUMAN MOLECULAR GENETICS
Volume 23, Issue 5, Pages 1333-1344Publisher
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddt523
Keywords
-
Funding
- National Institutes of Health (NIH) [R21 AR063360]
- Muscular Dystrophy Association (MDA)
- [RC2 DA028902-NIH]
Ask authors/readers for more resources
Valosin-containing protein (VCP)-associated disease caused by mutations in the VCP gene includes combinations of a phenotypically heterogeneous group of disorders such as hereditary inclusion body myopathy, Paget's disease of bone, frontotemporal dementia and amyotrophic lateral sclerosis. Currently, there are no effective treatments for VCP myopathy or dementia. VCP mouse models carrying the common R155H mutation include several of the features typical of the human disease. In our previous investigation, VCPR155H/R155H homozygous mice exhibited progressive weakness and accelerated pathology prior to their early demise. Herein, we report that feeding pregnant VCPR155H/+ heterozygous dams with a lipid-enriched diet (LED) results in the reversal of the lethal phenotype in VCPR155H/R155H homozygous offspring. We examined the effects of this diet on homozygous and wild-type mice from birth until 9 months of age. The LED regimen improved survival, motor activity, muscle pathology and the autophagy cascade. A targeted lipidomic analysis of skeletal muscle and liver revealed elevations in tissue levels of non-esterified palmitic acid and ceramide (d18:1/16:0), two lipotoxic substances, in the homozygous mice. The ability to reverse lethality, increase survival, and ameliorate myopathy and lipids deficits in the VCPR155H/R155H homozygous animals suggests that lipid supplementation may be a promising therapeutic strategy for patients with VCP-associated neurodegenerative diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available